Tag
A landmark study in Circulation reveals that CMR-quantified tricuspid regurgitant fraction (TRF) ≥20% significantly increases mortality risk, while liver extracellular volume (L-ECV) mapping provides a novel, potent biomarker for systemic c
Recent findings from the ARIC study reveal that integrating cardiac biomarkers and echocardiography with the PREVENT-HF score significantly enhances the prediction of incident heart failure, identifying high-risk individuals who traditional
This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic
This multi-national analysis of 2.92 million deaths highlights a concerning trend: while coronary and stroke mortality have plummeted, heart failure mortality remains stagnant or rising, with people with diabetes bearing a disproportionate
This review evaluates AI algorithms predicting heart failure risk from noisy single-lead ECGs, synthesizing evidence from large multinational cohorts, highlighting improved risk stratification with AI-ECG models beyond traditional clinical
In the FINEARTS‑HF trial, cardiovascular deaths comprised half of fatalities in HF with EF ≥40%, with sudden death accounting for the largest share — especially when EF was <50%. Finerenone did not clearly reduce cause‑specific mortality
The FINEARTS-HF trial demonstrates finerenone’s efficacy and safety in reducing heart failure events, improving symptoms, and lowering new-onset diabetes risk, with consistent benefits across sex, ejection fraction ranges, frailty levels, a
A Danish nationwide cohort study found that initiating SGLT2 inhibitors rather than mineralocorticoid receptor antagonists (MRAs) as the third foundational therapy after RASI and beta‑blocker in HFrEF was associated with lower all‑cause and
In HFrEF, eGFR often falls progressively for up to a year before heart-failure hospitalization or death. Monitoring eGFR trajectories provides earlier risk signals than single cut-offs and may identify patients for closer decongestion or th
This review synthesizes the pivotal EMPEROR-Preserved Trial results, highlighting empagliflozin’s efficacy in reducing heart failure outcomes in patients with preserved ejection fraction.
A phase 3 randomized trial found intracoronary infusion of allogeneic Wharton’s jelly mesenchymal stem cells (WJ-MSCs) after STEMI reduced new-onset heart failure and HF readmissions and improved LVEF versus standard care over a median 33-m
A large clinical trial compared Mobile Integrated Health with standard care coordination for heart failure patients after hospital discharge, finding no significant overall benefits but highlighting potential age-related effects.
Phase 1 study of AB-1002 (cardiotropic AAV delivering I-1c) in 11 patients with nonischemic HFrEF showed feasibility, no treatment-attributed SAEs, transient LFT elevations at higher dose, and preliminary signals of improved LVEF and NYHA c
This study reveals that both low and high ambient temperatures significantly increase mortality risk among Swedish heart failure patients, highlighting the need for climate adaptation strategies in high-latitude regions.
A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.
Pooled data from VICTORIA and VICTOR trials demonstrate that vericiguat significantly reduces cardiovascular death and heart failure hospitalization in a wide spectrum of patients with heart failure and reduced ejection fraction, including
The VICTOR trial evaluated vericiguat in HFrEF patients without recent worsening, showing no significant reduction in composite cardiovascular death or heart failure hospitalization, but fewer cardiovascular and all-cause deaths with accept
A prospective study reveals transthyretin cardiac amyloidosis (ATTR-CA) affects a significant proportion of older Black patients with heart failure, especially men over 75, with nearly half linked to the V142I genetic variant. Hispanic prev
A multicenter trial shows cardiac MRI offers comparable sensitivity to invasive coronary angiography for diagnosing ischemic cardiomyopathy, reducing invasive procedures in newly diagnosed heart failure patients.
The VICTOR trial in stable HFrEF patients shows vericiguat does not significantly reduce the composite of cardiovascular death or heart failure hospitalization but lowers cardiovascular and all-cause mortality, highlighting its potential fo
